Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rodeghiero

Showing results (31-40 of 266) with videos related to

Pageof 27
Sort By:
Thrombosis and Haemostasis|March 1, 1995
No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's diseaseG Castaman, F Rodeghiero
Thrombosis Research|May 4, 2010
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impactF Elice, F Rodeghiero
Thrombosis Research|December 27, 2011
Hematologic malignancies and thrombosisF Elice, F Rodeghiero
La Ricerca in Clinica E in Laboratorio|April 1, 1990
The von Willebrand factorF Rodeghiero, G Castaman
Drugs|October 1, 1995
Current management of von Willebrand's diseaseG Castaman, F Rodeghiero
Thrombosis and Haemostasis|August 1, 1996
The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen--relationship with physiological variables and establishment of reference rangesF Rodeghiero, A Tosetto
Journal of Thrombosis and Haemostasis : JTH|April 22, 2005
Provisional criteria for the diagnosis of VWD type 1J E Sadler, F Rodeghiero,
Haematologica|November 1, 1990
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemiaG Castaman, F Rodeghiero, E Dini
Journal of Thrombosis and Haemostasis : JTH|August 13, 2003
Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA ProjectA Tosetto, M Frezzato, F Rodeghiero
Haematologica|November 1, 1993
Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazolC Schiavotto, G Castaman, F Rodeghiero
Pageof 27

Showing results (31-40 of 266) with videos related to

Sort By:
Pageof 27
Thrombosis and Haemostasis|March 1, 1995
No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's diseaseG Castaman, F Rodeghiero
Thrombosis Research|May 4, 2010
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impactF Elice, F Rodeghiero
Thrombosis Research|December 27, 2011
Hematologic malignancies and thrombosisF Elice, F Rodeghiero
La Ricerca in Clinica E in Laboratorio|April 1, 1990
The von Willebrand factorF Rodeghiero, G Castaman
Drugs|October 1, 1995
Current management of von Willebrand's diseaseG Castaman, F Rodeghiero
Thrombosis and Haemostasis|August 1, 1996
The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen--relationship with physiological variables and establishment of reference rangesF Rodeghiero, A Tosetto
Journal of Thrombosis and Haemostasis : JTH|April 22, 2005
Provisional criteria for the diagnosis of VWD type 1J E Sadler, F Rodeghiero,
Haematologica|November 1, 1990
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemiaG Castaman, F Rodeghiero, E Dini
Journal of Thrombosis and Haemostasis : JTH|August 13, 2003
Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA ProjectA Tosetto, M Frezzato, F Rodeghiero
Haematologica|November 1, 1993
Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazolC Schiavotto, G Castaman, F Rodeghiero
Pageof 27